Drug Safety Evaluation 3e
Seiten
2017
Wiley-Blackwell (Hersteller)
978-1-119-09744-0 (ISBN)
Wiley-Blackwell (Hersteller)
978-1-119-09744-0 (ISBN)
- Keine Verlagsinformationen verfügbar
- Artikel merken
"Provides practical guidance to solve scientific and regulatory issues in preclinical safety assessment, early clinical drug development, and post-approval impurity issues"--Provided by publisher.
This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics.
Helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development
Explains scientific and philosophical bases for evaluation of specific concerns - including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity
Covers the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars
Revises material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation
Adds almost 20% new and thoroughly updates existing content from the last edition
This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics.
Helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development
Explains scientific and philosophical bases for evaluation of specific concerns - including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity
Covers the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars
Revises material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation
Adds almost 20% new and thoroughly updates existing content from the last edition
Shayne Cox Gad, BS, PhD, DABT, has more than 39 years of experience in regulatory toxicology, drug and device development, statistics, and risk assessment. He is Principal of Gad Consulting Services, a firm with eight employees and more than 500 clients worldwide in the pharmaceutical and medical device industries. He is Past President of the American College of Toxicology (ACT), the Roundtable of Toxicology Consultants, and three of the Society of Toxicology's specialty sections. Dr. Gad received the 2008 ACT Lifetime Contribution Award and has authored or edited 47 books (10 with Wley) and more than 350 chapters, articles, and abstracts. Has preparated 110 INDs and 8 NDAs and teaches 3-5 professional education courses a year.
| Erscheint lt. Verlag | 3.1.2017 |
|---|---|
| Verlagsort | Hoboken |
| Sprache | englisch |
| Maße | 150 x 250 mm |
| Gewicht | 666 g |
| Themenwelt | Naturwissenschaften ► Chemie |
| ISBN-10 | 1-119-09744-4 / 1119097444 |
| ISBN-13 | 978-1-119-09744-0 / 9781119097440 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Online Resource (2024)
Pearson Education Limited (Hersteller)
CHF 84,50
Online Resource (2024)
Pearson Education Limited (Hersteller)
CHF 45,90
Freischaltcode (2024)
Pearson Education Limited (Hersteller)
CHF 83,80
